Arbutus BiopharmaABUS -2.69%53 Current Ratio is 54.26 as of Mar. 2026, which is 378% above its 10-year median of 11.35. GuruFocus rates ABUS with a GF Score™ of 53/100 and a GF Value™ of $51.42 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,417 Biotechnology companies, Arbutus Biopharma ranks better than 98.66% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Arbutus Biopharma's current ratio for the quarter that ended in Mar. 2026 was 54.26.
Arbutus Biopharma has a current ratio of 54.26. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Arbutus Biopharma's Current Ratio or its related term are showing as below:
ABUS'
s Current Ratio Range Over the Past 10 Years
Min: 4.6 Med: 11.35 Max: 54.26
Current: 54.26
During the past 13 years, Arbutus Biopharma's highest Current Ratio was 54.26. The lowest was 4.60. And the median was 11.35.
ABUS's Current Ratio is ranked better than 98.66% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs ABUS: 54.26
Arbutus Biopharma (NAS:ABUS) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Arbutus Biopharma Current Ratio Related Terms
Arbutus Biopharma Current Ratio Historical Data
* Premium members only.
The historical data trend for Arbutus Biopharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABUS vs SPRY, KURA, JANX: Current Ratio Comparison
For the Biotechnology subindustry, Arbutus Biopharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arbutus Biopharma Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where Arbutus Biopharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arbutus Biopharma (ABUS) has a Current Ratio of 54.26 as of Mar. 2026. This is 378% above median its historical median of 11.35. Over the past decade, Arbutus Biopharma's Current Ratio has ranged from 4.60 to 54.26. According to the industry distribution chart, Arbutus Biopharma ranks #19 out of 1417 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Arbutus Biopharma's Current Ratio too high?
Arbutus Biopharma's current Current Ratio of 54.26 is 378% above median its 10-year median of 11.35. Over the past 10 years, this metric has ranged from a low of 4.60 to a high of 54.26. The Biotechnology industry median Current Ratio is 3.89. Arbutus Biopharma's value of 54.26 is 1294.9% above this industry median. Based on the distribution chart, Arbutus Biopharma ranks #19 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arbutus Biopharma has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's Current Ratio compare to SPRY and KURA?
According to the Biotechnology industry distribution chart, Arbutus Biopharma ranks #19 out of 1417 companies for Current Ratio. This places Arbutus Biopharma in the top 1% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Arbutus Biopharma's value of 54.26 is 1294.9% above this benchmark. Historically, Arbutus Biopharma's own Current Ratio has ranged from 4.60 to 54.26 over the past decade. While the company's 10-year median is 11.35 vs. the industry median of 3.89, Arbutus Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arbutus Biopharma's current Current Ratio of 54.26 is 1294.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arbutus Biopharma's current Current Ratio is 54.26, which is 378% above median its own 10-year median of 11.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Arbutus Biopharma (ABUS) is currently considered Possible Value Trap. The stock's GF Value™ is $51.42, compared to a current price of $4.34 — trading 91.6% below its estimated fair value. The current Current Ratio is 54.26, which is 378% above median its 10-year median of 11.35 and 1294.9% above the Biotechnology industry median of 3.89. Arbutus Biopharma's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Arbutus Biopharma (ABUS), the current Current Ratio is 54.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arbutus Biopharma (ABUS) Overvalued in 2026?
Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued.
The current stock price of $4.34 is trading 91.6% below its estimated GF Value™ of $51.42.
GuruFocus considers Arbutus Biopharma to be Possible Value Trap.
Key valuation signals for ABUS:
Current Ratio: 54.26 (378% above median its 10-year median of 11.35)
GF Value™: $51.42 vs. price of $4.34 (91.6% below fair value)
Industry Position: 1294.9% above the Biotechnology median (#19 of 1417)
No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
53GF Score
Get the complete analysis for ABUS
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABUS has been successfully added to your 
